top of page

Anxiety Disorder

Statistics on Anxiety:

Anxiety disorders are the most common mental illness in the U.S., affecting 40 million adults in the United States age 18 and older, or 18.1% of the population every year.

Anxiety disorders are highly treatable, yet only 36.9% of those suffering receive treatment.

People with an anxiety disorder are three to five times more likely to go to the doctor and six times more likely to be hospitalized for psychiatric disorders than those who do not suffer from anxiety disorders.
(Source: Anxiety and Depression Association of America ADAA,
https://adaa.org/about-adaa/press-room/facts-statistics)

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug

Schier, Alexandre de Mello, et al.

Revista Brasileira de Psiquiatria. 2012 Jun, 34(1) (online article).

Modulation of Fear and Anxiety by the Endogenous Cannabinoid System

Chhatwal, James P., et al.

CNS. 2007 Mar, 12(3): 211-220 (Full).

Effects of cannabinoids on the anxiety-like response in mice

Rutkowska, Maria, et al.

Pharmacological Reports. 2006, 58: 200-206 (Full).

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Zuardi, A.W., et al.

Brazilian Journal of Medical and Biological Research. 2006 Apr, 39(4): 421-429 (Full).

Pharmacological Evaluation of Cannabinoid Receptor Ligands in a Mouse Model of Anxiety: Further Evidence for an Anxiolytic Role for Endogenous Cannabinoid Signaling

Patel, Sachin, et al.

Journal of Pharmacology and Experimental Therapeutics. 2006 Mar 28, 318(1): 304-311 (Full).

Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects

Jiang, Wen, et al.

The Journal of Clinical Investigation. 2005 Nov 1, 115(11): 3104-3116 (Full).

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report

Crippa, Jose Alexandre S., et al.

Journal of Psychopharmacology. 2010 Sep 9, 25(1): 121-130 (abstract).

Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs

Gaetani, Silvana, et al.

International Review of Neurobiology. 2009, 85: 57-72 (abstract).

Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test

Moreira, Fabricio A., et al.

Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006 Dec 30, 30(8): 1466-1471 (abstract).

A role for cannabinoid CB1 receptors in mood and anxiety disorders

Witkin, J.M., et al.

Behavioral Pharmacology. 2005 Sep, 16(5-6): 315-331 (abstract).

Endocannabinoid system and stress and anxiety responses

Viveros, M.P., et al.

Pharmacology Biochemistry and Behavior. 2005 Jun, 81(2): 331-342 (abstract).

Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts

McPartland, John M., et al.

Journal of Cannabis Therapeutics. 2001, 1(3-4): 103-32 (abstract).

Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects

Zuardi, A.W., et al.

Psychopharmacology. 1982 Mar, 76(3): 245-250 (abstract).

The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety

Fabre, Louis F., et al.

The Journal of Clinical Pharmacology. 1981 Aug, 21(S1): 377-382 (abstract).

Anxiety Disorder: About Us

bottom of page